Home › Ovarian Cancer › Rhode Island
Ovarian Cancer clinical trials in Rhode Island
16 studies for Ovarian Cancer are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Women & Infants Hospital /ID# 277930, Providence
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 1, 2026 · NCT07024784TLR9 Immunotherapy for Peritoneal Carcinomatosis
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07658196A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Women & Infants Hospital /ID# 274716, Providence
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Women & Infants Hospital ( Site 0001), Providence
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Women & Infants Hospital ( Site 0050), Providence
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07001748A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Women and Infants Hospital, Providence
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Women and Infants Hospital, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Lifespan Cancer Institute - Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- Women's and Infant's Hospital, Providence
RecruitingHealthy volunteers welcome
Ages 50 to 74 · Women · Updated May 6, 2026 · NCT00539162A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0191, Providence
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.